Potential therapeutic roles of tanshinone IIA in human bladder cancer cells

International Journal of Molecular Sciences

Volumn 15, Issue 9, 2014, Pages 15622-15637

  Chiu, Sheng Chun ^a   Huang, Sung Ying ^b   Chang, Shu Fang ^a   Chen, Shee Ping ^c   Chen, Chi Cheng ^a,d   Lin, Tien Huang ^a,d   Liu, Hsin Ho ^a,d   Tsai, Tsung Hsun ^a,d   Lee, Shang Sen ^a,d   Pang, Cheng Yoong ^c,d   Hsieh, Teng Fu ^a,d  

^a Taichung Tzu Chi Hospital   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Bladder cancer; Cisplatin; Combination therapy; Metastasis; Tanshinone IIA

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; TANSHINONE IIA; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; TANSHINONE;

APOPTOSIS; ARTICLE; BLADDER CANCER; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METASTASIS; MITOCHONDRION; NICK END LABELING; SURVIVAL RATE; TUMOR INVASION; WESTERN BLOTTING; WOUND CLOSURE; BLADDER TUMOR; CELL MOTION; DRUG EFFECTS; EPITHELIUM CELL; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DITERPENES, ABIETANE; EPITHELIAL CELLS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84908331394     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150915622     Document Type: Article

References (36)

1. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61, 212-236.
2. Lutzeyer, W.; Rubben, H.; Dahm, H. Prognostic parameters in superficial bladder-cancer-An analysis of 315 cases. J. Urol. 1982, 127, 250-252.
3. Wu, X.R. Urothelial tumorigenesis: A tale of divergent pathways. Nat. Rev. Cancer 2005, 5, 713-725.
4. Botteman, M.F.; Pashos, C.L.; Redaelli, A.; Laskin, B.; Hauser, R. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003, 21, 1315-1330.
5. Mariotto, A.B.; Yabroff, K.R.; Shao, Y.; Feuer, E.J.; Brown, M.L. Projections of the cost of cancer care in the United States: 2010-2020. J. Natl. Cancer Inst. 2011, 103, 117-128.
6. Xu, D.; Lin, T.H.; Zhang, C.; Tsai, Y.C.; Li, S.; Zhang, J.; Yin, M.; Yeh, S.; Chang, C. The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells. Prostate 2012, 72, 803-816.
7. Chen, J.; Shi, D.Y.; Liu, S.L.; Zhong, L. Tanshinone IIA induces growth inhibition and apoptosis in gastric cancer in vitro and in vivo. Oncol. Rep. 2012, 27, 523-528.
8. Dong, Y.; Morris-Natschke, S.L.; Lee, K.H. Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Nat. Prod. Rep. 2011, 28, 529-542.
9. Zhou, L.; Zuo, Z.; Chow, M.S. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 2005, 45, 1345-1359.
10. Chiu, S.C.; Huang, S.Y.; Chen, S.P.; Su, C.C.; Chiu, T.L.; Pang, C.Y. Tanshinone IIA inhibits human prostate cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo. Prostate Cancer Prostatic Dis. 2013, 16, 315-322.
11. Wang, J.; Wang, X.; Jiang, S.; Yuan, S.; Lin, P.; Zhang, J.; Lu, Y.; Wang, Q.; Xiong, Z.; Wu, Y.; et al. Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J. Neurooncol. 2007, 82, 11-21.
12. Wang, X.; Wei, Y.; Yuan, S.; Liu, G.; Lu, Y.; Zhang, J.; Wang, W. Potential anticancer activity of tanshinone IIA against human breast cancer. Int. J. Cancer 2005, 116, 799-807.
13. Yuan, S.L.; Wei, Y.Q.; Wang, X.J.; Xiao, F.; Li, S.F.; Zhang, J. Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J. Gastroenterol. 2004, 10, 2024-2028.
14. Pan, T.L.; Wang, P.W.; Hung, Y.C.; Huang, C.H.; Rau, K.M. Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways. Proteomics 2013, 13, 3411-3423.
15. Yan, M.Y.; Chien, S.Y.; Kuo, S.J.; Chen, D.R.; Su, C.C. Tanshinone IIA inhibits BT-20 human breast cancer cell proliferation through increasing caspase 12, GADD153 and phospho-p38 protein expression. Int. J. Mol. Med. 2012, 29, 855-863.
16. Zhang, Y.; Wei, R.X.; Zhu, X.B.; Cai, L.; Jin, W.; Hu, H. Tanshinone IIA induces apoptosis and inhibits the proliferation, migration, and invasion of the osteosarcoma MG-63 cell line in vitro. Anticancer Drugs 2012, 23, 212-219.
17. Wang, W.Q.; Liu, L.; Sun, H.C.; Fu, Y.L.; Xu, H.X.; Chai, Z.T.; Zhang, Q.B.; Kong, L.Q.; Zhu, X.D.; Lu, L.; et al. Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. J. Hematol. Oncol. 2012, 5, 69. doi:10.1186/1756-8722-5-69.
18. Shan, Y.F.; Shen, X.; Xie, Y.K.; Chen, J.C.; Shi, H.Q.; Yu, Z.P.; Song, Q.T.; Zhou, M.T.; Zhang, Q.Y. Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacol. Sin. 2009, 30, 1537-1542.
19. Nizamutdinova, I.T.; Lee, G.W.; Lee, J.S.; Cho, M.K.; Son, K.H.; Jeon, S.J.; Kang, S.S.; Kim, Y.S.; Lee, J.H.; Seo, H.G.; et al. Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis 2008, 29, 1885-1892.
20. Aggarwal, B.B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006, 71, 1397-1421.
21. Chan, S.E.; Lai, H.W.; Su, C.C.; Kuo, S.J.; Chien, S.Y.; Lin, H.Y.; Chen, D.R. Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An in Vitro Study. Evid.-Based Complement. Altern. Med.: eCAM 2011, 2011, 841564:1-841564:9.
22. Cheng, C.Y.; Su, C.C. Tanshinone IIA may inhibit the growth of small cell lung cancer H146 cells by up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial membrane potential. Mol. Med. Rep. 2010, 3, 645-650.
23. Cheng, C.Y.; Su, C.C. Tanshinone IIA inhibits Hep-J5 cells by increasing calreticulin, caspase 12 and GADD153 protein expression. Int. J. Mol. Med. 2010, 26, 379-385.
24. Chien, S.Y.; Kuo, S.J.; Chen, Y.L.; Chen, D.R.; Cheng, C.Y.; Su, C.C. Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. Mol. Med. Rep. 2012, 5, 282-286.
25. Chiu, T.L.; Su, C.C. Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int. J. Mol. Med. 2010, 25, 231-236.
26. Su, C.C.; Chien, S.Y.; Kuo, S.J.; Chen, Y.L.; Cheng, C.Y.; Chen, D.R. Tanshinone IIA inhibits human breast cancer MDA-MB-231 cells by decreasing LC3-II, Erb-B2 and NF-kappaBp65. Mol. Med. Rep. 2012, 5, 1019-1022.
27. Chang, L.C.; Wu, C.L.; Liu, C.W.; Chuo, W.H.; Li, P.C.; Tsai, T.R. Preparation, characterization and cytotoxicity evaluation of tanshinone IIA nanoemulsions. J. Biomed. Nanotechnol. 2011, 7, 558-567.
28. Mothana, R.A.; Jansen, R.; Gruenert, R.; Bednarski, P.J.; Lindequist, U. Antimicrobial and cytotoxic abietane diterpenoids from the roots of Meriandera benghalensis (Roxb.) Benth. Die Pharm. 2009, 64, 613-615.
29. Su, C.C.; Chen, G.W.; Lin, J.G. Growth inhibition and apoptosis induction by tanshinone I in human colon cancer Colo 205 cells. Int. J. Mol. Med. 2008, 22, 613-618.
30. Gupta, G.P.; Massague, J. Cancer metastasis: Building a framework. Cell 2006, 127, 679-695.
31. Szarvas, T.; vom Dorp, F.; Ergun, S.; Rubben, H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat. Rev. Urol. 2011, 8, 241-254.
32. Soga, N.; Arima, K.; Sugimura, Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int. J. Urol. 2008, 15, 800-803.
33. Von der Maase, H.; Sengelov, L.; Roberts, J.T.; Ricci, S.; Dogliotti, L.; Oliver, T.; Moore, M.J.; Zimmermann, A.; Arning, M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005, 23, 4602-4608.
34. Longley, D.B.; Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol. 2005, 205, 275-292.
35. Drayton, R.M.; Catto, J.W. Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev. Anticancer Ther. 2012, 12, 271-281.
36. Jiao, J.W.; Wen, F. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncol. Rep. 2011, 25, 781-788.